DE69919156D1 - Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkung - Google Patents
Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkungInfo
- Publication number
- DE69919156D1 DE69919156D1 DE69919156T DE69919156T DE69919156D1 DE 69919156 D1 DE69919156 D1 DE 69919156D1 DE 69919156 T DE69919156 T DE 69919156T DE 69919156 T DE69919156 T DE 69919156T DE 69919156 D1 DE69919156 D1 DE 69919156D1
- Authority
- DE
- Germany
- Prior art keywords
- oxyiminoalkanic
- hypoglykemic
- acid derivatives
- hypolipidemic effect
- hypolipidemic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP12792198 | 1998-05-11 | ||
JP12792198 | 1998-05-11 | ||
JP12792298 | 1998-05-11 | ||
JP12792298 | 1998-05-11 | ||
PCT/JP1999/002407 WO1999058510A1 (en) | 1998-05-11 | 1999-05-10 | Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69919156D1 true DE69919156D1 (de) | 2004-09-09 |
DE69919156T2 DE69919156T2 (de) | 2005-11-03 |
Family
ID=26463748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69919156T Expired - Lifetime DE69919156T2 (de) | 1998-05-11 | 1999-05-10 | Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkung |
Country Status (27)
Country | Link |
---|---|
US (3) | US6251926B1 (de) |
EP (2) | EP1077957B1 (de) |
JP (1) | JP2000198772A (de) |
KR (1) | KR100388120B1 (de) |
CN (1) | CN1148361C (de) |
AR (1) | AR029876A1 (de) |
AT (1) | ATE272625T1 (de) |
AU (1) | AU766831B2 (de) |
BR (1) | BR9910371A (de) |
CA (1) | CA2331879A1 (de) |
CO (1) | CO5040066A1 (de) |
DE (1) | DE69919156T2 (de) |
ES (1) | ES2226377T3 (de) |
HK (1) | HK1034972A1 (de) |
HU (1) | HUP0103714A3 (de) |
ID (1) | ID28699A (de) |
IL (1) | IL139470A0 (de) |
LV (1) | LV12606B (de) |
MY (1) | MY123337A (de) |
NO (1) | NO317426B1 (de) |
NZ (1) | NZ508066A (de) |
PE (1) | PE20000625A1 (de) |
PL (1) | PL344002A1 (de) |
PT (1) | PT1077957E (de) |
RU (1) | RU2213738C2 (de) |
SK (1) | SK16412000A3 (de) |
WO (1) | WO1999058510A1 (de) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2331879A1 (en) * | 1998-05-11 | 1999-11-18 | Takeda Chemical Industries, Ltd. | Oxyiminoalkanoic acid derivatives |
TWI249401B (en) * | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
DK1206457T3 (da) | 1999-08-27 | 2004-02-16 | Lilly Co Eli | Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER |
DE19948126A1 (de) * | 1999-10-06 | 2001-04-12 | Max Delbrueck Centrum | Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock |
TW558554B (en) | 1999-10-29 | 2003-10-21 | Takeda Chemical Industries Ltd | Crystals of oxyiminoalkanoic acid derivative |
CA2389208A1 (en) | 1999-10-29 | 2001-05-10 | Takeda Chemical Industries, Ltd. | Process for the preparation of oxyiminoalkanoic acid derivatives |
CZ20021604A3 (cs) | 1999-11-10 | 2002-09-11 | Takeda Chemical Industries, Ltd. | Pětičlenné N-heterocyklické sloučeniny, farmaceutický přípravek a činidlo je obsahující a jejich použití |
KR20020060227A (ko) * | 1999-11-10 | 2002-07-16 | 다케다 야쿠힌 고교 가부시키가이샤 | 체중 증가 억제제 |
EP1229026A4 (de) * | 1999-11-10 | 2003-09-24 | Takeda Chemical Industries Ltd | Alkoxyiminoalkansäure-derivate |
CA2403903A1 (en) * | 2000-03-28 | 2002-09-26 | Masatoshi Hazama | Angiogenesis inhibitors |
WO2002014291A1 (en) * | 2000-08-11 | 2002-02-21 | Nippon Chemiphar Co.,Ltd. | PPARδ ACTIVATORS |
US20060089389A1 (en) * | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
PE20020617A1 (es) * | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
EP1357115B1 (de) | 2000-12-28 | 2009-06-17 | Takeda Pharmaceutical Company Limited | Alkansäurederivate, verfahren zu deren herstellung und deren verwendung |
WO2002076959A1 (fr) * | 2001-03-23 | 2002-10-03 | Takeda Chemical Industries, Ltd. | Derive heterocyclique a cinq membres d'acide alcanoique |
ATE480236T1 (de) * | 2001-04-25 | 2010-09-15 | Takeda Pharmaceutical | Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans |
EP1790353A1 (de) * | 2001-12-29 | 2007-05-30 | Novo Nordisk A/S | Kombinierte Verwendung einer GLP-1-Verbidnung und eines Modulators für Spätfolgen bei Diabetes |
TWI343915B (en) * | 2002-10-07 | 2011-06-21 | Hoffmann La Roche | Chirale ppar agonists |
AU2003278929A1 (en) * | 2002-10-18 | 2004-05-13 | Amylin Pharmaceuticals, Inc. | Treatment of pancreatitis with amylin |
WO2004041266A1 (ja) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
US20050014264A1 (en) * | 2002-12-11 | 2005-01-20 | University Of Massachusetts | Method of introducing siRNA into adipocytes |
US7790681B2 (en) * | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
US20040209803A1 (en) * | 2002-12-19 | 2004-10-21 | Alain Baron | Compositions for the treatment and prevention of nephropathy |
WO2004060399A1 (ja) * | 2002-12-27 | 2004-07-22 | Takeda Pharmaceutical Company Limited | 体重増加抑制剤 |
US7625916B2 (en) * | 2003-09-17 | 2009-12-01 | Kaname Kawasugi | Medicinal composition |
WO2005082841A1 (en) * | 2004-02-24 | 2005-09-09 | Irm Llc | Immunosuppressant compounds and compositions |
KR20070011329A (ko) * | 2004-03-29 | 2007-01-24 | 상꾜 가부시키가이샤 | 인슐린 저항성 개선제를 함유하는 당뇨병 치료제 |
US7517910B2 (en) | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
JP4880591B2 (ja) | 2004-06-04 | 2012-02-22 | テバ ファーマシューティカル インダストリーズ リミティド | イルベサルタンを含む医薬組成物 |
WO2006030753A1 (ja) * | 2004-09-13 | 2006-03-23 | Santen Pharmaceutical Co., Ltd. | 角結膜障害治療剤 |
US7556933B2 (en) * | 2004-10-01 | 2009-07-07 | Luminultra Technologies Ltd. | Reagent system and process for adenosine triphosphate monitoring |
JP5094394B2 (ja) | 2005-04-20 | 2012-12-12 | 武田薬品工業株式会社 | 縮合複素環化合物 |
JP5000490B2 (ja) | 2005-04-28 | 2012-08-15 | 武田薬品工業株式会社 | チエノピリミドン化合物 |
US7781469B2 (en) | 2005-05-27 | 2010-08-24 | Shionogi & Co., Ltd. | Arylacetate derivatives having isoxazole skeleton |
MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
US7491414B2 (en) * | 2005-10-12 | 2009-02-17 | Gaia Herbs, Inc. | Anti-inflammatory substances extracted from Echinacea |
US8318746B2 (en) | 2007-04-27 | 2012-11-27 | Takeda Pharmaceutical Company Limited | Nitrogen-containing five-membered heterocyclic compound |
JPWO2009128481A1 (ja) | 2008-04-16 | 2011-08-04 | 武田薬品工業株式会社 | 含窒素5員複素環化合物 |
US20110230428A1 (en) * | 2008-07-22 | 2011-09-22 | John Wityak | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
EP2322222A4 (de) | 2008-08-07 | 2011-12-21 | Takeda Pharmaceutical | Therapeutikum für reizdarmsyndrom |
CA2782776A1 (en) | 2008-12-04 | 2010-06-10 | Ikfe Gmbh | Biomarkers for atherosclerosis |
WO2010067207A1 (en) | 2008-12-11 | 2010-06-17 | Ikfe Gmbh | Biomarkers for insulin sensitizer drug response |
WO2010076655A1 (en) | 2008-12-30 | 2010-07-08 | Ikfe Gmbh | Biomarkers for adipose tissue activity |
US20100210541A1 (en) | 2009-01-07 | 2010-08-19 | Andreas Pfuetzner | Biomarkers for Appetite Regulation |
CN102875548A (zh) * | 2011-07-14 | 2013-01-16 | 中国科学院大连化学物理研究所 | 一类基于肟的通过[2+2+2]环加成合成吡啶衍生物的方法 |
KR20140072037A (ko) | 2011-08-30 | 2014-06-12 | 씨에이치디아이 파운데이션, 인코포레이티드 | 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법 |
MY166890A (en) | 2011-08-30 | 2018-07-24 | Chdi Foundation Inc | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
WO2013082106A1 (en) | 2011-12-02 | 2013-06-06 | The General Hospital Corporation | Differentiation into brown adipocytes |
US9630976B2 (en) | 2012-07-03 | 2017-04-25 | Ono Pharmaceutical Co., Ltd. | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes |
CN105593221B (zh) | 2013-09-30 | 2017-09-22 | 小野药品工业株式会社 | 具有生长抑素受体激动活性的化合物及其药物用途 |
EP3083587B1 (de) * | 2013-12-16 | 2018-04-04 | Cadila Healthcare Limited | Oximinoderivate zur behandlung von dyslipidämie |
EA034528B1 (ru) | 2014-07-17 | 2020-02-17 | Сиэйчдиай Фаундэйшн, Инк. | Способ лечения нарушений, связанных с вич |
FR3042903B1 (fr) * | 2015-10-21 | 2017-12-08 | Commissariat Energie Atomique | Utilisation d'acides hydroxyiminoalcanoiques comme agents anti-nitreux dans des operations de desextraction reductrice du plutonium |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
BR112019016433A2 (pt) | 2017-02-08 | 2020-04-07 | Ono Pharmaceutical Co | composto que apresenta atividade agonística do receptor de somatostatina e uso farmacêutico do mesmo |
CN113507865A (zh) | 2019-02-21 | 2021-10-15 | 斯特尔凯斯公司 | 身体支撑组件和用于该身体支撑组件的使用和组装的方法 |
US11357329B2 (en) | 2019-12-13 | 2022-06-14 | Steelcase Inc. | Body support assembly and methods for the use and assembly thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU177578B (en) | 1976-08-27 | 1981-11-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing new 0-/3-amino-2-hydroxy-propyl/-amidoxime derivatives |
JPS5849382A (ja) | 1981-09-18 | 1983-03-23 | Kyowa Hakko Kogyo Co Ltd | β−ラクタム化合物 |
JPS59167576A (ja) | 1983-03-15 | 1984-09-21 | Kyowa Hakko Kogyo Co Ltd | β−ラクタム化合物 |
JPS6277391A (ja) | 1984-12-21 | 1987-04-09 | Mochida Pharmaceut Co Ltd | セフアロスポリン誘導体、その製法およびそれらを有効成分とする抗菌剤 |
JPS62158290A (ja) * | 1985-12-28 | 1987-07-14 | Banyu Pharmaceut Co Ltd | 新規セフアロスポリン誘導体 |
US4698338A (en) * | 1986-02-19 | 1987-10-06 | Eli Lilly And Company | 7[2-(2-aminothiazol-4-yl)-2-benzyloximino]acetamido-3[4-alkyl-5-oxo-6-hydroxy-3,4-dihydro-1,2,4-triazin-3-yl]thiomethyl cephalosporins |
US5750532A (en) * | 1986-12-10 | 1998-05-12 | Schering Corporation | Pharmaceutically active compounds |
JPH0277391A (ja) | 1988-09-14 | 1990-03-16 | Suzuki Motor Co Ltd | 水ジェット推進船のビルジ水排水装置 |
DE68905765T3 (de) | 1988-11-21 | 1998-03-26 | Zeneca Ltd | Fungizide. |
EP0400805A1 (de) | 1989-04-25 | 1990-12-05 | Toshiyasu Ishimaru | Cephalosporinverbindungen und ihre Verwendung |
JPH03115272A (ja) * | 1989-10-19 | 1991-05-16 | Banyu Pharmaceut Co Ltd | マンデル酸誘導体およびその製法 |
IL98506A (en) * | 1990-06-18 | 1996-09-12 | Fujisawa Pharmaceutical Co | Peptides, of antibiotics, processes for their preparation and pharmaceutical preparations containing them |
ES2110421T5 (es) * | 1990-06-27 | 2004-12-01 | Basf Aktiengesellschaft | O-bencil-oximeteres y los agentes protectores de las plantas que contienen estos compuestos. |
JPH04112890A (ja) * | 1990-09-04 | 1992-04-14 | Ajinomoto Co Inc | 新規チアゾール誘導体及び該誘導体を含有する抗菌剤 |
EP0486011A3 (en) * | 1990-11-16 | 1992-07-15 | Fujisawa Pharmaceutical Co., Ltd. | Pharmaceutical composition against pneumocystis carinii |
CA2100918C (en) * | 1992-07-21 | 1997-01-21 | Nobuyuki Hamanaka | Oxime derivative |
US5512581A (en) | 1994-07-18 | 1996-04-30 | Abbott Laboratories | Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis |
CH689228A5 (de) | 1994-10-07 | 1998-12-31 | Novartis Ag | Oximether, sowie diese enthaltende Pflanzenschutzmittel. |
CZ261095A3 (en) | 1994-10-07 | 1996-04-17 | Sankyo Co | Oxime derivatives, process of their preparation, pharmaceutical composition containing thereof and their use |
US5902726A (en) | 1994-12-23 | 1999-05-11 | Glaxo Wellcome Inc. | Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma |
US6022897A (en) | 1995-04-25 | 2000-02-08 | The Salk Institute For Biological Studies | Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
WO1996038427A1 (fr) * | 1995-06-02 | 1996-12-05 | Sankyo Company, Limited | Derives d'oxyimino aromatiques |
US5939442A (en) | 1995-06-07 | 1999-08-17 | The Salk Institute For Biological Studies | Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof |
FR2737893B1 (fr) * | 1995-08-16 | 1997-09-12 | Roussel Uclaf | Nouvelles cephalosporines comportant en position 7, un radical benzyloxyimino substitue, leur procede et intermediaires de preparation, leur application comme medicaments |
GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
JPH09323929A (ja) | 1996-04-02 | 1997-12-16 | Sankyo Co Ltd | オキシム誘導体を含有する医薬 |
CZ318098A3 (cs) | 1996-04-04 | 1999-01-13 | Sankyo Company, Limited | Deriváty fenylalkylkarboxylové kyseliny, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
AU4050797A (en) | 1996-08-02 | 1998-02-25 | Ligand Pharmaceuticals Incorporated | Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators |
JP4427825B2 (ja) | 1997-07-24 | 2010-03-10 | アステラス製薬株式会社 | コレステロール低下作用を有する医薬組成物 |
JPH11193272A (ja) | 1997-10-01 | 1999-07-21 | Sankyo Co Ltd | フェニルアルキルカルボン酸誘導体を含有する医薬 |
CA2331879A1 (en) * | 1998-05-11 | 1999-11-18 | Takeda Chemical Industries, Ltd. | Oxyiminoalkanoic acid derivatives |
-
1999
- 1999-05-10 CA CA002331879A patent/CA2331879A1/en not_active Abandoned
- 1999-05-10 EP EP99918355A patent/EP1077957B1/de not_active Expired - Lifetime
- 1999-05-10 PL PL99344002A patent/PL344002A1/xx not_active Application Discontinuation
- 1999-05-10 MY MYPI99001832A patent/MY123337A/en unknown
- 1999-05-10 ES ES99918355T patent/ES2226377T3/es not_active Expired - Lifetime
- 1999-05-10 KR KR10-2000-7000081A patent/KR100388120B1/ko not_active IP Right Cessation
- 1999-05-10 CN CNB998060070A patent/CN1148361C/zh not_active Expired - Fee Related
- 1999-05-10 NZ NZ508066A patent/NZ508066A/xx unknown
- 1999-05-10 HU HU0103714A patent/HUP0103714A3/hu unknown
- 1999-05-10 SK SK1641-2000A patent/SK16412000A3/sk unknown
- 1999-05-10 PT PT99918355T patent/PT1077957E/pt unknown
- 1999-05-10 EP EP04075569A patent/EP1428531A1/de not_active Withdrawn
- 1999-05-10 AU AU36297/99A patent/AU766831B2/en not_active Ceased
- 1999-05-10 ID IDW20002324A patent/ID28699A/id unknown
- 1999-05-10 AT AT99918355T patent/ATE272625T1/de not_active IP Right Cessation
- 1999-05-10 WO PCT/JP1999/002407 patent/WO1999058510A1/en not_active Application Discontinuation
- 1999-05-10 BR BR9910371-0A patent/BR9910371A/pt not_active IP Right Cessation
- 1999-05-10 US US09/423,854 patent/US6251926B1/en not_active Expired - Fee Related
- 1999-05-10 IL IL13947099A patent/IL139470A0/xx unknown
- 1999-05-10 AR ARP990102190A patent/AR029876A1/es unknown
- 1999-05-10 RU RU2000131183/04A patent/RU2213738C2/ru not_active IP Right Cessation
- 1999-05-10 DE DE69919156T patent/DE69919156T2/de not_active Expired - Lifetime
- 1999-05-11 CO CO99029123A patent/CO5040066A1/es unknown
- 1999-05-11 PE PE1999000393A patent/PE20000625A1/es not_active Application Discontinuation
- 1999-12-28 JP JP11373202A patent/JP2000198772A/ja active Pending
-
2000
- 2000-11-01 LV LVP-00-148A patent/LV12606B/en unknown
- 2000-11-02 NO NO20005531A patent/NO317426B1/no unknown
- 2000-11-16 US US09/714,699 patent/US6495581B1/en not_active Expired - Fee Related
-
2001
- 2001-08-15 HK HK01105750A patent/HK1034972A1/xx not_active IP Right Cessation
-
2002
- 2002-12-27 US US10/331,056 patent/US6924300B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69919156D1 (de) | Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkung | |
DE60012213D1 (de) | Fünfgliedrige n-heterocyclen mit hypoglykämischer und hypolipidemischer wirkung | |
EE200200251A (et) | Uued N-asabitsükloamiidi derivaadid ja nende kasutamine | |
EE05169B1 (et) | Asendatud oksasolidinoonid ja nende kasutamine | |
DE69913233D1 (de) | Kosmetische zusammensetzung | |
ATE234817T1 (de) | Hetaroylcyclohexandionderivate mit herbizider wirkung | |
EE200200175A (et) | Asendatud 2-tio-3,5-ditsüano-4-arüül-6-aminopüridiinid ja nende kasutamine | |
ATE326939T1 (de) | Kosmetische zusammensetzung | |
DE69726729D1 (de) | Fungizide mittel mit verbesserter bioverfügbarkeit | |
DE60025147D1 (de) | Kosmetische Zusammensetzung und Verwendungen | |
DE69904147D1 (de) | Juckreizstillende agentien in kosmetische mittel | |
DE60014893D1 (de) | Pyrazolobenzodiazepine mit cdk2 hemmender wirkung | |
DE69831233D1 (de) | Barbitursaure derivaten mit antimetastatischer und antitumorischer wirkung | |
DE69934805D1 (de) | Substituierte imidazole mit cytokin-inhibierender wirkung | |
ID28698A (id) | Formulasi antiparasit | |
ID29635A (id) | Formulasi mikrokapsul | |
DE59708160D1 (de) | 1-Dimethylaminomethyl-2-phenyl-cycloalk-2-enverbindungen mit analgetischer Wirkung | |
ID30114A (id) | Zat-zat herbisida dengan fenoksisulfonilurea tersubstitusi | |
EE200000621A (et) | Pikornaviirusevastased ühendid, nende valmistamine ja kasutamine | |
PT1139761E (pt) | Composicoes herbicidas e concentrados tensioactivos | |
DE69903143D1 (de) | Chromanon und thiochromanon derivate | |
EE200100347A (et) | 3,3-biarüülpiperidiini ja 2,2-biarüülmorfoliini derivaadid | |
ID27655A (id) | Formulasi mikrokapsul | |
DE69916694D1 (de) | 2-Hydroxy-5-methyl-hexan-3-on und 3-hydroxy-5-methyl-hexan-2-on | |
DE69904738D1 (de) | 2-phenylpyran-4-one derivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP |
|
8364 | No opposition during term of opposition |